Provided by Tiger Fintech (Singapore) Pte. Ltd.

ENGENE HOLDINGS INC

4.00
+0.01000.25%
Post-market: 4.000.00000.00%16:05 EDT
Volume:71.68K
Turnover:287.49K
Market Cap:203.91M
PE:-2.59
High:4.39
Open:3.99
Low:3.90
Close:3.99
Loading ...

Company Profile

Company Name:
ENGENE HOLDINGS INC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
57
Office Location:
4868 Rue Levy,Suite 220,Montreal,Quebec,Canada
Zip Code:
H4R 2P1
Fax:
- -
Introduction:
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Directors

Name
Position
Jason D. Hanson
Chief Executive Officer and Director
Richard Glickman
Chairman of the Board
Gerry Brunk
Director
Jasper Bos
Director
Lota Zoth
Director

Shareholders

Name
Position
Jason D. Hanson
Chief Executive Officer and Director
Alex Nichols
President and Chief Operating Officer
Ryan Daws
Chief Financial Officer
Anthony T. Cheung
Chief Technology Officer
James C. Sullivan
Chief Scientific Officer
Richard Bryce
Chief Medical Officer